Biocon Limited Q4 FY26 Earnings Call: Revenue Up 10%, EBITDA Jumps 29%
Biocon Limited reported Q4 FY26 total revenue of ₹4,569 crore, up 10% YoY, and EBITDA of ₹1,073 crore, up 29% YoY. For FY26, revenue reached ₹17,270 crore (up 14% YoY) and EBITDA was ₹3,798 crore (up 25% YoY). The company completed its integration phase and is focusing on execution and value creation.
The announcement details significant financial growth, strategic completion of integration, and future focus on execution and margin improvement, which are material factors for investors and the company's market position.
The company reported strong year-on-year growth in revenue and EBITDA for both the quarter and the full fiscal year, indicating positive financial performance and successful completion of integration phases.
Biocon Limited has announced its Q4 FY26 and Full Year FY26 earnings. The company reported a total revenue of ₹4,569 crore for Q4 FY26, a 10% increase year-on-year (YoY), and ₹17,270 crore for the full year FY26, a 14% increase YoY. EBITDA for Q4 FY26 stood at ₹1,073 crore, marking a significant 29% YoY jump, with a 23% margin. For the full year, EBITDA was ₹3,798 crore, a 25% increase YoY, with a 22% margin. The company highlighted that FY26 represents a clear inflection point, with the transition from an integration and investment phase to execution and value creation completed. The integration of Biocon Biologics into Biocon has been successfully finalized, simplifying the structure and enabling better capital allocation. Major capacity expansions across biosimilars, insulins, peptides, and complex generics are substantially complete, with the focus now shifting to improving utilization and expanding margins. The balance sheet has been strengthened with meaningful progress on deleveraging. In the Biosimilars segment, Q4 revenues grew 12% YoY to ₹2,756 crore, with EBITDA up 33% YoY to ₹720 crore, achieving a 26% margin. For FY26, Biosimilars revenue was ₹10,431 crore, up 16% YoY, and EBITDA was ₹2,751 crore, up 40% YoY. The Generics segment saw Q4 revenues grow 13% YoY (adjusted) to ₹847 crore, driven by new launches. For FY26, Generics revenue grew 17% YoY (adjusted) to ₹3,168 crore. The CRDMO segment reported Q4 revenue of ₹1,037 crore, up 2% YoY, and FY26 revenue of ₹3,739 crore, up 3% YoY. The company is focused on scaling up biosimilar launches and improving profitability in generics for FY27.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.